2023
Mortality, incarceration and cost implications of fentanyl felonization laws: A modeling study
Savinkina A, Jurecka C, Gonsalves G, Barocas J. Mortality, incarceration and cost implications of fentanyl felonization laws: A modeling study. International Journal Of Drug Policy 2023, 121: 104175. PMID: 37729682, PMCID: PMC10840895, DOI: 10.1016/j.drugpo.2023.104175.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidDrug OverdoseFentanylHumansOpiate OverdoseOpioid-Related DisordersUnited StatesEstimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics
Jawa R, Tin Y, Nall S, Calcaterra S, Savinkina A, Marks L, Kimmel S, Linas B, Barocas J. Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics. JAMA Network Open 2023, 6: e237888. PMID: 37043198, PMCID: PMC10098970, DOI: 10.1001/jamanetworkopen.2023.7888.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineCost-Benefit AnalysisHumansLife ExpectancyPrimary Health CareConceptsIncremental cost-effectiveness ratioPrimary care practitionersClinical outcomesPCP servicesPrimary careAddiction servicesAddiction careUS primary care clinicsLong-term clinical outcomesHealth care sector costsInjection-related infectionsPrimary care clinicsHealth care sector perspectivePrimary care practicesCost-effectiveness ratioObservational cohortBuprenorphine prescribingCare clinicsClinical trialsPCP practicesTreatment strategiesMAIN OUTCOMESimulated cohortCare practitionersCare practicesEstimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts
Chatterjee A, Weitz M, Savinkina A, Macmadu A, Madushani R, Potee R, Ryan D, Murphy S, Walley A, Linas B. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts. JAMA Network Open 2023, 6: e237036. PMID: 37058306, PMCID: PMC10105308, DOI: 10.1001/jamanetworkopen.2023.7036.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineDrug OverdoseHumansMassachusettsNaltrexoneOpioid-Related DisordersConceptsIncremental cost-effectiveness ratioIncremental costCost-effectiveness ratioEconomic evaluationEconomic studiesOpioid use disorderXR-naltrexoneOverdose deathsTreatment startQALYOverdose mortalityUse disordersCostExtended-release naltrexoneTreatment costsDiscontinue medicationsMOUD accessQALYsOpen cohortMost prisonsIncarcerated individualsMOUD treatmentTreatment strategiesMoneyFatal overdoses
2022
Population‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis
Savinkina A, Madushani RWMA, Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis. Addiction 2022, 117: 2450-2461. PMID: 35315162, PMCID: PMC9377514, DOI: 10.1111/add.15879.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioOpioid use disorderStandard of careUse disordersFatal overdosesDetox patientsMOUD initiationWithdrawal programInitiation of medicationHealth care sector perspectiveRisk of overdoseFatal opioid overdosesCost-effectiveness ratioCost-effectiveness analysisOpioid useHealth care spendingOutpatient careDetox programsOpioid overdosesMOUDPatientsOverdosesPopulation-level impactDisorder populationHealth effectsModeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs
Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs. Addiction 2022, 117: 2635-2648. PMID: 35315148, PMCID: PMC9951221, DOI: 10.1111/add.15883.Peer-Reviewed Original ResearchConceptsSyringe services programFatal opioid overdosesBuprenorphine-naloxone treatmentOpioid use disorderTreatment initiationBuprenorphine treatmentOpioid overdosesFatal overdosesSSP clientsActive opioid useCommunity treatment providersObservational cohort studyNational surveillance dataCost-effectiveness analysisCohort studyIntervention scenariosOpioid useBuprenorphine programOUD treatmentStatus quo scenarioClinical trialsFatal overdoseMore QALYsUse disordersTreatment engagementSimulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use–Associated Infective Endocarditis
Adams JW, Savinkina A, Hudspeth JC, Gai MJ, Jawa R, Marks LR, Linas BP, Hill A, Flood J, Kimmel S, Barocas JA. Simulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use–Associated Infective Endocarditis. JAMA Network Open 2022, 5: e220541. PMID: 35226078, PMCID: PMC8886538, DOI: 10.1001/jamanetworkopen.2022.0541.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalgesics, OpioidAnti-Bacterial AgentsAnti-Infective AgentsCost-Benefit AnalysisEndocarditisEndocarditis, BacterialFemaleHumansMaleConceptsOutpatient parenteral antimicrobial therapyIncremental cost-effectiveness ratioOral antibiotic therapyInjection drug use-associated infective endocarditisUsual care strategyAntibiotic therapyOpioid drug useAntibiotic treatment strategiesAntibiotic strategiesCare servicesTreatment strategiesCare strategiesTreatment discontinuationClinical outcomesInfective endocarditisDrug use-associated infective endocarditisDrug useInpatient intravenous antibiotic therapyLong-term clinical outcomesHigher treatment completion rateIntravenous antibiotic therapyObservational cohort studyPercentage of patientsPostacute care facilityParenteral antimicrobial therapy
2020
Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study
Barocas JA, Yazdi G, Savinkina A, Nolen S, Savitzky C, Samet JH, Englander H, Linas BP. Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. Clinical Infectious Diseases 2020, 73: e3661-e3669. PMID: 32901815, PMCID: PMC8662770, DOI: 10.1093/cid/ciaa1346.Peer-Reviewed Original ResearchConceptsInjection opioid useRisk of deathAge 60 yearsOpioid useInfective endocarditisOpioid epidemicMortality rateUS opioid epidemicSyringe services programLow-risk techniqueProbability of deathHarm reduction approachAttributable fractionRisk groupsNatural historyInjection behaviorModel-generated estimatesDeathOpioidsSignificant increaseInjection frequencyUnited StatesMortalityRiskEpidemic